Congenica, a Cambridge, England, UK-based global clinical decision support platform provider, raised a further £13.25m ($17.1m) in Series B funding.
The total amount raised across its Series B financings is now £23.3m ($30.1m).
The round, which brought total funding raised to date to £26m ($33.5m), was led by Parkwalk Advisors, with participation from Digital China Health Technologies Corporation Limited (DCHealth) and existing investors.
The company intends to use the funds to:
– accelerate growth, with commercial scale-up to support further penetration into international markets, and expand on the initial focus of the US and China,
– develop an enhanced product platform that harnesses the power of statistics and machine learning technology to augment the ability of users to make diagnostic decisions.
Led by Dr David Atkins, CEO, Congenica is the provider of the diagnostic decision support platform, SapientiaTM, and associated clinical services, which enable clinicians to interrogate the human genome to identify disease-causing variants.
The company was recently awarded a multi-year contract to be the exclusive provider of Diagnostic Decision Support Services for the world leading NHS Genomic Medicine Service, allowing clinicians to use its Sapientia™ platform and expert support services to interrogate the human genome to identify disease-causing variants.